AI Article Synopsis
- Ovarian steroid cell tumor, not otherwise specified (SCT-NOS), is a rare tumor type linked to symptoms like excessive hair growth and masculinization.
- A case report describes a patient who had a previous yolk sac tumor and elevated serum CA72-4 levels when diagnosed with SCT-NOS, which was later confirmed through histopathological examination.
- Genetic analysis revealed ten mutations in various genes, suggesting potential underlying mechanisms of the tumor.
Article Abstract
Ovarian steroid cell tumor, not otherwise specified (SCT-NOS), is a rare subtype of sex cord-stromal tumor, characterized by hirsutism and virilization. There are, however, few tumor markers reported in the tumor. The following is a case report. Six years ago, the patient underwent a left adnexectomy after being diagnosed with a yolk sac tumor. Her serum CA72-4 levels were significantly elevated when she was diagnosed with SCT-NOS. She suffered from hirsutism and oligomenorrhea with long menstrual cycles. SCT-NOS was confirmed by her histopathological examination. When the tumor was diagnosed, serum CA72-4 levels were elevated. Following tumor resection, serum CA72-4 levels returned to the average reference interval. Whole-exome sequencing (WES) was utilized to identify ten mutations in MKI67, TICAM1, CHD3, ARID5B, ERBB4, POLD1, FZR1, MTCP1, TBX3, and CLTC genes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/09513590.2024.2400943 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Construction of exosome non-coding RNA feature for non-invasive, early detection of gastric cancer patients by machine learning: a multi-cohort study.
Gut
January 2025
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China
Background And Objective: Gastric cancer (GC) remains a prevalent and preventable disease, yet accurate early diagnostic methods are lacking. Exosome non-coding RNAs (ncRNAs), a type of liquid biopsy, have emerged as promising diagnostic biomarkers for various tumours. This study aimed to identify a serum exosome ncRNA feature for enhancing GC diagnosis.
View Article and Find Full Text PDFPrognostic impact and reasons for variability by tumor location in gastric cancer.
World J Gastroenterol
November 2024
Zhejiang Cancer Hospital, Hangzhou Institute of Medicine, Chinese Academy of Sciences, Hangzhou 310022, Zhejiang Province, China.
Background: Gastric cancer (GC) is a highly prevalent gastrointestinal tract tumor. Several trials have demonstrated that the location of GC can affect patient prognosis. However, the factors determining tumor location remain unclear.
View Article and Find Full Text PDFSerum tumor markers (carcinoembryonic antigen, carbohydrate antigen 19-9, carbohydrate antigen 72-4, carbohydrate antigen 24-2, ferritin) and gastric cancer prognosis correlation.
World J Gastrointest Surg
September 2024
Department of Clinical Laboratory, Huangshi Central Hospital (Affiliated Hospital of Hubei Polytechnic University), Hubei Key Laboratory of Kidney Disease Pathogenesis and Intervention, Huangshi Tumor Molecular Diagnosis and Treatment Key Laboratory, Huangshi 435000, Hubei Province, China.
Background: Gastric cancer is a kind of malignant tumor which is prevalent all over the world. Although some progress has been made in the treatment of gastric cancer, its prognosis is still not optimistic, so it is of great significance to find reliable prognostic indicators to guide the treatment and management of patients with gastric cancer.
Aim: To explore the relationship between serum levels of five biomarkers [carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 19-9, CA72-4, CA24-2, and ferritin] and prognosis in patients with gastric cancer.
Impact of oxaliplatin and trastuzumab combination therapy on tumor markers and T lymphocyte subsets for advanced gastric cancer.
World J Gastrointest Oncol
September 2024
Department of Thyroid Surgery, The Affiliated Hospital of Southwest Medical University, Luzhou 646000, Sichuan Province, China.
Article Synopsis
- Advanced gastric cancer (AGC) has a poor prognosis, but combining oxaliplatin and trastuzumab shows potential for improving treatment outcomes by targeting both tumor markers and T lymphocyte subsets.
- In a study with 60 AGC patients, the combination therapy led to significant reductions in serum tumor markers (CEA, CA19-9, CA72-4) and increased levels of CD3+ and CD4+ T lymphocytes after six treatment cycles.
- Patients demonstrating a substantial decrease in tumor markers and an increase in the CD4+/CD8+ T cell ratio had better clinical responses, indicating the potential of these factors as predictive biomarkers for treatment efficacy.
Impact of dynamic changes of tumor marker in neoadjuvant chemotherapy-treated triple-negative gastric cancer patients: a multi-center study.
BMC Cancer
September 2024
Department of Gastric Surgery, Fujian Medical University Union Hospital, No. 29 Xinquan Road, Fuzhou, Fujian Province, 350001, China.
Background: Independent and valid prognostic predictors for locally advanced gastric cancer (LAGC) patients with non-elevated serum tumor markers (Triple-negative: CA199 < 37U/ml, CEA < 5 µg/ml and CA125 < 35U/ml) before and after neoadjuvant chemotherapy (NACT) remain unclear.
Methods: A total of 352 LAGC patients treated with NACT(NLAGC) from two centers were included. Of the 156 were Triple-negative patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!